European CHMP recommends approval of ixekizumab for the treatment of adults with active axial spondyloarthritis

The CHMP has issued a positive opinion, recommending its approval for the treatment of ankylosing spondylitis with inadequate response to conventional therapy, and non-radiographic axial spondyloarthritis with objective signs of inflammation and inadequate response to NSAIDs.


European Medicines Agency